Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
80 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Hyperphosphatemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Hyperphosphatemia - Pipeline Review, H1 2015', provides an overview of the Hyperphosphatemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of table 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hyperphosphatemia Overview 7 Therapeutics Development 8 Pipeline Products for Hyperphosphatemia - Overview 8 Pipeline Products for Hyperphosphatemia - Comparative Analysis 9 Hyperphosphatemia - Therapeutics under Development by Companies 10 Hyperphosphatemia - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Hyperphosphatemia - Products under Development by Companies 15 Hyperphosphatemia - Companies Involved in Therapeutics Development 16 Astellas Pharma Inc. 16 AstraZeneca PLC 17 Medice Arzneimittel Putter GmbH & Co. KG 18 Mitsubishi Tanabe Pharma Corporation 19 OPKO Health, Inc. 20 Panion & Bf Biotech Inc 21 Sanofi 22 Spectrum Pharmaceuticals, Inc. 23 Toray Industries, Inc. 24 Vifor Pharma AG 25 Hyperphosphatemia - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 32 Drug Profiles 34 ASP-3325 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 colestilan chloride - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Fe-SAMMS - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 fermagate - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ferric citrate - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 JPH-101 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 niacinamide - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 PT-20 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 RDX-002 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 SPI-014 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 sucroferric oxyhydroxide - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 tenapanor hydrochloride - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 TRK-390 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 VS-501 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 VS-505 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Hyperphosphatemia - Recent Pipeline Updates 57 Hyperphosphatemia - Dormant Projects 68 Hyperphosphatemia - Discontinued Products 69 Hyperphosphatemia - Product Development Milestones 70 Featured News & Press Releases 70 Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 70 Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis 70 Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 71 Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms 72 Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia 73 Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate 74 Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 74 Oct 23, 2014: Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014 75 Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 77 Sep 05, 2014: Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 77 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80
List of Tables Number of Products under Development for Hyperphosphatemia, H1 2015 8 Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Comparative Analysis by Late Stage Development, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Hyperphosphatemia - Pipeline by Astellas Pharma Inc., H1 2015 16 Hyperphosphatemia - Pipeline by AstraZeneca PLC, H1 2015 17 Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H1 2015 18 Hyperphosphatemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 19 Hyperphosphatemia - Pipeline by OPKO Health, Inc., H1 2015 20 Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2015 21 Hyperphosphatemia - Pipeline by Sanofi, H1 2015 22 Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 23 Hyperphosphatemia - Pipeline by Toray Industries, Inc., H1 2015 24 Hyperphosphatemia - Pipeline by Vifor Pharma AG, H1 2015 25 Assessment by Monotherapy Products, H1 2015 26 Number of Products by Stage and Target, H1 2015 28 Number of Products by Stage and Mechanism of Action, H1 2015 30 Number of Products by Stage and Route of Administration, H1 2015 31 Number of Products by Stage and Molecule Type, H1 2015 33 Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H1 2015 57 Hyperphosphatemia - Dormant Projects, H1 2015 68 Hyperphosphatemia - Discontinued Products, H1 2015 69
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
